Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models

Journal: Nature Communications

Published: 2018-05-22

DOI: 10.1038/s41467-018-04356-9

Affiliations: 17

Authors: 47

Go to article
Institutions FC
Broad Institute of MIT and Harvard, United States of America (USA) 0.23
Department of Medical Oncology, DFCI, United States of America (USA) 0.22
Aileron Therapeutics, Inc., United States of America (USA) 0.11
Harvard Medical School (HMS), United States of America (USA) 0.08
Department of Biostatistics and Computational Biology (BCB), DFCI, United States of America (USA) 0.04
Center for Functional Cancer Epigenetics (CFCE), DFCI, United States of America (USA) 0.04
Department of Pathology and Laboratory Medicine, Cornell University, United States of America (USA) 0.04
USC Department of Pathology, United States of America (USA) 0.04
Department of Pathology, MSKCC, United States of America (USA) 0.04
UAB Comprehensive Cancer Center, United States of America (USA) 0.04
Department of Pathology, BWH, United States of America (USA) 0.03
Department of Pathology, MGH, United States of America (USA) 0.02
Center for Cancer Genome Discovery (CCGD), DFCI, United States of America (USA) 0.02
Department of Medicine, MSKCC, United States of America (USA) 0.02
Department of Pediatric Oncology, DFCI, United States of America (USA) 0.01
Boston Children's Hospital (BCH), United States of America (USA) 0.01

Return